PMID- 14966417 OWN - NLM STAT- MEDLINE DCOM- 20040329 LR - 20191210 IS - 0041-1337 (Print) IS - 0041-1337 (Linking) VI - 77 IP - 3 DP - 2004 Feb 15 TI - Beneficial effect of matching at the HLA-A and -B amino-acid triplet level on rejection-free clear graft survival in penetrating keratoplasty. PG - 417-21 AB - OBJECTIVE: The beneficial effect of human leukocyte antigen (HLA) matching on long-term prognosis in penetrating keratoplasty is now unequivocal but has to be weighed against the additional waiting period on an individual basis. HLAMatchmaker is a molecularly based algorithm for histocompatibility determination that can identify immunologically acceptable mismatches and thus potentially reduce time on the waiting list dramatically without negatively affecting prognosis. METHODS: The HLAMatchmaker algorithm (triplet-string matching) was applied on each of 545 normal-risk keratoplasties for which complete HLA type was known at split-level resolution. Two homogeneous groups were defined. Group I consisted of the 147 penetrating keratoplasties with up to 13 triplet-string mismatches (the typical upper limit of foreign in case of a single HLA-A or HLA-B allele mismatch) and was compared to the remaining 398 patients with more triplet mismatches (group II) using the Kaplan-Meier method and log-rank statistics. Analysis of clear graft survival on the basis of conventional HLA-A and HLA-B matching was performed as well. Reduction of time on the waiting list as compared to conventional HLA-A and HLA-B matching was predicted individually. RESULTS: Triplet-string matching yielded 85% rejection-free clear graft survival 3 years after penetrating keratoplasty in group I but only 76% in group II (P<0.05), whereas conventional HLA-A and HLA-B matching did not result in any statistically significant reduction of immune reactions because of lack of statistical power (P=0.08). Triplet-string matching (13 mismatches accepted) reduces median time on the waiting list by 80%. CONCLUSIONS: Triplet-string matching seems to improve mid- to long-term prognosis in penetrating keratoplasties while simultaneously reducing time on the waiting list in most cases. It should thus be considered for histocompatibility determination in penetrating keratoplasty. FAU - Bohringer, Daniel AU - Bohringer D AD - Eye Hospital and LIONS Cornea Bank Baden-Wurttemberg, University Hospital, Albert-Ludwigs-Universitat Freiburg, Freiburg, Germany. boehringer@aug.ukl.uni-freiburg.de FAU - Reinhard, Thomas AU - Reinhard T FAU - Duquesnoy, Rene J AU - Duquesnoy RJ FAU - Bohringer, Stefan AU - Bohringer S FAU - Enczmann, Jurgen AU - Enczmann J FAU - Lange, Peter AU - Lange P FAU - Claas, Frans AU - Claas F FAU - Sundmacher, Rainer AU - Sundmacher R LA - eng PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Transplantation JT - Transplantation JID - 0132144 RN - 0 (HLA-A Antigens) RN - 0 (HLA-B Antigens) SB - IM MH - Aged MH - Female MH - Graft Rejection/etiology MH - *Graft Survival MH - HLA-A Antigens/*genetics MH - HLA-B Antigens/*genetics MH - Histocompatibility Testing/*standards MH - Humans MH - *Keratoplasty, Penetrating MH - Male MH - Middle Aged MH - Proportional Hazards Models MH - *Repetitive Sequences, Amino Acid MH - Risk MH - Time Factors MH - Waiting Lists EDAT- 2004/02/18 05:00 MHDA- 2004/03/30 05:00 CRDT- 2004/02/18 05:00 PHST- 2004/02/18 05:00 [pubmed] PHST- 2004/03/30 05:00 [medline] PHST- 2004/02/18 05:00 [entrez] AID - 10.1097/01.TP.0000110415.10401.94 [doi] PST - ppublish SO - Transplantation. 2004 Feb 15;77(3):417-21. doi: 10.1097/01.TP.0000110415.10401.94.